CO2021017656A2 - Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades - Google Patents

Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades

Info

Publication number
CO2021017656A2
CO2021017656A2 CONC2021/0017656A CO2021017656A CO2021017656A2 CO 2021017656 A2 CO2021017656 A2 CO 2021017656A2 CO 2021017656 A CO2021017656 A CO 2021017656A CO 2021017656 A2 CO2021017656 A2 CO 2021017656A2
Authority
CO
Colombia
Prior art keywords
diseases
treatment
pharmaceutical compositions
hypersecretion
new compounds
Prior art date
Application number
CONC2021/0017656A
Other languages
English (en)
Inventor
Béranger Duthion
Luke Jonathan Alvey
Florence Marie-Emilie Bonnaterre
Denis Bucher
Hélène Marie Jary
Christophe Peixoto
Nicolas Desroy
Amynata Tirera
Taoues Temal-Laïb
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CO2021017656A2 publication Critical patent/CO2021017656A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención da a conocer compuestos según la Fórmula I: donde R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y y Z son como se definen en el presente documento. La presente invención se refiere a compuestos, métodos para su producción, composiciones farmacéuticas que comprenden los mismos, y métodos de tratamiento que utilizan los mismos, para la profilaxis y/o tratamiento de enfermedades inflamatorias, enfermedades autoinflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, enfermedades fibróticas, rechazo de trasplantes, enfermedades que implican una alteración del recambio cartilaginoso, malformación congénita del cartílago, enfermedades que implican una alteración del recambio óseo, enfermedades asociadas a la hipersecreción de IL-6, enfermedades asociadas a la hipersecreción de TNFα, interferones, IL-12 y/o IL-23, enfermedades respiratorias, enfermedades endocrinas y/o metabólicas, enfermedades cardiovasculares, enfermedades dermatológicas, y/o enfermedades asociadas a la angiogénesis anormal mediante la administración del compuesto de la invención.
CONC2021/0017656A 2019-05-29 2021-12-22 Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades CO2021017656A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
PCT/EP2020/064368 WO2020239658A1 (en) 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
CO2021017656A2 true CO2021017656A2 (es) 2022-01-17

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017656A CO2021017656A2 (es) 2019-05-29 2021-12-22 Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades

Country Status (21)

Country Link
US (1) US20220340548A1 (es)
EP (1) EP3976189A1 (es)
JP (1) JP2022534578A (es)
KR (1) KR20220015450A (es)
CN (1) CN113924146A (es)
AR (1) AR119028A1 (es)
AU (1) AU2020281650A1 (es)
BR (1) BR112021023900A2 (es)
CA (1) CA3141683A1 (es)
CL (1) CL2021003133A1 (es)
CO (1) CO2021017656A2 (es)
CR (1) CR20210586A (es)
EA (1) EA202193281A1 (es)
GB (1) GB201907616D0 (es)
IL (1) IL288375A (es)
MA (1) MA56019A (es)
MX (1) MX2021013803A (es)
PE (1) PE20220503A1 (es)
SG (1) SG11202112652RA (es)
TW (1) TW202110839A (es)
WO (1) WO2020239658A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020234859A1 (en) 2019-03-11 2021-09-16 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
WO2023066204A1 (zh) * 2021-10-18 2023-04-27 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
WO2024003209A1 (en) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis
WO2024104441A1 (en) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2642994A2 (en) * 2010-11-18 2013-10-02 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
ES2605946T3 (es) * 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ES2908283T3 (es) * 2017-12-02 2022-04-28 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用

Also Published As

Publication number Publication date
TW202110839A (zh) 2021-03-16
EA202193281A1 (ru) 2022-03-01
KR20220015450A (ko) 2022-02-08
AU2020281650A1 (en) 2022-02-03
US20220340548A1 (en) 2022-10-27
IL288375A (en) 2022-01-01
MA56019A (fr) 2022-04-06
WO2020239658A1 (en) 2020-12-03
JP2022534578A (ja) 2022-08-02
CL2021003133A1 (es) 2022-07-22
MX2021013803A (es) 2021-12-14
PE20220503A1 (es) 2022-04-07
BR112021023900A2 (pt) 2022-01-18
CN113924146A (zh) 2022-01-11
SG11202112652RA (en) 2021-12-30
CA3141683A1 (en) 2020-12-03
CR20210586A (es) 2022-01-24
GB201907616D0 (en) 2019-07-10
EP3976189A1 (en) 2022-04-06
AR119028A1 (es) 2021-11-17

Similar Documents

Publication Publication Date Title
CO2021017656A2 (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades
MX2020005423A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
CO2021000159A2 (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades
CO2020005200A2 (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios
UY34855A (es) Aminotriazolopiridina para usar el tratamiento de la inflamación y composiciones farmacéuticas de ella.
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
DOP2017000139A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
CO2022008359A2 (es) Derivados de un inhibidor de fgfr
AR086042A1 (es) Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
ECSP14001627A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
SG11201907909TA (en) Fgfr inhibitor and application thereof
UY35985A (es) Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios.
PH12016501677B1 (en) Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR122929A1 (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades
BR112022012126A2 (pt) Compostos antelmínticos compreendendo uma estrutura quinolínica
CO2021014223A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
UY36983A (es) Pirazolopiridinaminas sustituidas
PH12019501926A1 (en) New medical use of compound iii
UY30386A1 (es) Compuestos de amida del acido 3-amino-tieno(2,3b(beta)piridina-2- carboxilico sustituido, procesos para su preparacion y usos de los mismos